Repare Therapeutics (NASDAQ:RPTX) Now Covered by Analysts at Capital One Financial
Repare Therapeutics (NASDAQ:RPTX) Now Covered by Analysts at Capital One Financial
Capital One Financial initiated coverage on shares of Repare Therapeutics (NASDAQ:RPTX – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued an overweight rating and a $28.00 price objective on the stock.
Capital One Financial 开始对 Repare Therapeutics(纳斯达克股票代码:RPTX — 获取评级) Briefing.com报道,在周五上午发布的一份研究报告中。该公司对该股发布了增持评级和28.00美元的目标股价。
Separately, HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a buy rating on the stock in a research note on Thursday, November 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $30.80.
另外,HC Wainwright在11月17日星期四的一份研究报告中将Repare Therapeutics股票的目标股价从38.00美元下调至25.00美元,并对该股设定了买入评级。一位股票研究分析师对该股进行了持有评级,五位对该股发布了买入评级。根据MarketBeat的数据,该公司的共识评级为适度买入,共识目标价为30.80美元。
Repare Therapeutics Trading Down 5.5 %
Repare Therapeutics 交易下跌 5.
NASDAQ:RPTX opened at $13.46 on Friday. The firm has a market capitalization of $564.81 million, a price-to-earnings ratio of -18.44 and a beta of 0.11. The firm's fifty day simple moving average is $15.50 and its 200 day simple moving average is $13.94. Repare Therapeutics has a twelve month low of $8.06 and a twelve month high of $18.68.
纳斯达克股票代码:RPTX周五开盘价为13.46美元。该公司的市值为5.6481亿美元,市盈率为-18.44,beta值为0.11。该公司的五十天简单移动平均线为15.50美元,其200天简单移动平均线为13.94美元。Repare Therapeutics创下十二个月低点8.06美元,十二个月高点为18.68美元。
Insider Buying and Selling
内幕买入和卖出
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 30.30% of the stock is currently owned by insiders.
在相关新闻中,董事戴维斯·杰雷尔在12月9日星期五的一笔交易中出售了25万股Repare Therapeutics股票。这些股票的平均价格为16.00美元,总交易额为4,000,000.00美元。出售后,该董事现在拥有该公司2,094,451股股票,价值约为33,511,216美元。该交易是在向美国证券交易委员会提交的法律文件中披露的,该文件可通过以下方式获得 这个链接。目前,30.30%的股票由内部人士拥有。
Institutional Investors Weigh In On Repare Therapeutics
机构投资者对 Repare Therapeutics 进行了权衡
Hedge funds and other institutional investors have recently modified their holdings of the stock. Bartlett & Co. LLC bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $28,000. UBS Group AG increased its position in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after purchasing an additional 739 shares during the last quarter. Bpifrance SA bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $113,000. Tower Research Capital LLC TRC bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $113,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $143,000. Institutional investors own 78.19% of the company's stock.
对冲基金和其他机构投资者最近修改了该股的持有量。Bartlett & Co.LLC在第二季度购买了Repare Therapeutics的新股份,价值约28,000美元。瑞银集团股份公司在第三季度将其在Repare Therapeutics的股票头寸增加了26.3%。瑞银集团股份公司在上个季度又购买了739股股票后,现在拥有该公司3,551股股票,价值43,000美元。Bpifrance SA在第二季度购买了Repare Therapeutics的新股份,价值约11.3万美元。Tower Research Capital LLC TRC在第三季度购买了Repare Therapeutics的新股份,价值约11.3万美元。最后,Fox Run Management L.L.C. 在第三季度购买了Repare Therapeutics的新股份,价值约14.3万美元。机构投资者拥有该公司78.19%的股票。
About Repare Therapeutics
关于 Repare Therapeu
(Get Rating)
(获取评分)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare Therapeutics Inc是一家临床阶段的精准肿瘤学公司,通过在加拿大和美国使用其合成致死性方法发现和开发治疗药物。该公司使用其专有的、全基因组且支持CRISPR的平台SnipRX来系统地发现和开发高度靶向的癌症疗法,这些疗法侧重于基因组不稳定性,包括DNA损伤修复。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- 3 Airline Stocks Taking Off in 2023
- Why Wall Street Has Bullish Targets on Target Stock
- What Macy's Guidance Means For Retail
- Fortinet Stock Price Bumpy, Here Is Why
- Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
- 免费获取 StockNews.com 关于 Repare Therapeutics (RPTX) 的研究报告的副本
- 3 只航空股将在 2023 年上涨
- 为什么华尔街对目标股票设定看涨目标
- 梅西百货的指导对零售意味着什么
- Fortinet 股价颠簸,这就是原因
- 分析师评级后,Apexigen股票飙升,是时候买入了吗?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Repare Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Repare Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。